PubRank

Vernon K Sondak

Author PubWeight™ 207.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009 23.08
2 Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008 8.09
3 PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011 4.80
4 Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009 4.32
5 Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002 3.05
6 Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008 2.88
7 Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010 2.83
8 The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012 2.31
9 Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010 2.30
10 Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003 2.23
11 The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 2005 2.12
12 Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol 2008 2.11
13 Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008 2.09
14 Chemotherapy for metastatic melanoma: time for a change? Cancer 2007 1.99
15 Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012 1.92
16 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012 1.81
17 Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011 1.78
18 Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013 1.77
19 Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 2012 1.68
20 A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011 1.66
21 The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007 1.64
22 Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008 1.61
23 Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 2002 1.57
24 Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol 2008 1.55
25 Interferon alfa-2a for melanoma metastases. Lancet 2002 1.55
26 Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004 1.50
27 Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med 2010 1.47
28 The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013 1.46
29 Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 2003 1.42
30 Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow? Ann Surg Oncol 2008 1.42
31 Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 2008 1.41
32 Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol 2008 1.38
33 Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol 2011 1.35
34 Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer 2003 1.35
35 Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010 1.35
36 CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol 2008 1.28
37 Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003 1.24
38 Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer 2013 1.23
39 Ipilimumab. Nat Rev Drug Discov 2011 1.20
40 Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys 2011 1.17
41 Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control 2009 1.15
42 New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2011 1.12
43 Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res 2013 1.10
44 Retroperitoneal sarcomas. Cancer Imaging 2005 1.09
45 Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 2013 1.09
46 c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009 1.08
47 Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys 2007 1.07
48 Point: Interferon-alpha for adjuvant therapy for melanoma patients. J Natl Compr Canc Netw 2004 1.06
49 Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 2012 1.04
50 Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 2012 1.04
51 Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer 2003 1.03
52 Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 2008 1.03
53 Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 2010 1.02
54 Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010 1.02
55 Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011 1.02
56 Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002 1.02
57 Markers and tissue resources for melanoma: meeting report. Cancer Res 2006 1.01
58 Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 2008 1.01
59 Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 2008 1.01
60 Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control 2009 0.99
61 Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005 0.98
62 Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg 2011 0.98
63 Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 2013 0.98
64 Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol 2003 0.98
65 Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified. J Clin Oncol 2009 0.98
66 Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005 0.97
67 Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol 2012 0.97
68 A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol 2010 0.96
69 Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol 2013 0.96
70 Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol 2013 0.96
71 Melanoma in the brain: biology and therapeutic options. Melanoma Res 2012 0.95
72 Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005 0.94
73 Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer 2010 0.94
74 Case-control study of smoking and non-melanoma skin cancer. Cancer Causes Control 2011 0.93
75 Targeted therapy in melanoma. Clin Dermatol 2013 0.93
76 Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol 2009 0.93
77 Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol 2004 0.92
78 Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 2012 0.92
79 Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer 2008 0.92
80 Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control 2006 0.92
81 Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005 0.91
82 Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. Int J Cancer 2013 0.91
83 Gender disparities in patients with melanoma: breaking the glass ceiling. J Clin Oncol 2012 0.91
84 Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol 2014 0.91
85 The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 2012 0.91
86 Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013 0.90
87 The surgical management of primary and metastatic Merkel cell carcinoma. Curr Probl Cancer 2010 0.89
88 Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 2003 0.88
89 Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005 0.88
90 Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 2014 0.88
91 Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther 2013 0.88
92 Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis 2012 0.87
93 Novel treatments for melanoma brain metastases. Cancer Control 2013 0.87
94 Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer 2011 0.87
95 Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin. J Invest Dermatol 2013 0.87
96 Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep 2007 0.86
97 Pediatric melanoma: analysis of an international registry. Cancer 2013 0.86
98 Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol 2012 0.85
99 Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol 2013 0.85
100 Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol 2004 0.84
101 Melanoma: adjuvant therapy and other treatment options. Curr Treat Options Oncol 2003 0.84
102 Desmoplastic and neurotropic melanoma. Cancer 2004 0.84
103 Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis 2012 0.84
104 Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol 2002 0.83
105 Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Ann Surg Oncol 2006 0.83
106 Who is to blame for false-negative sentinel node biopsies in melanoma? Ann Surg Oncol 2010 0.83
107 Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study. BMC Cancer 2012 0.83
108 Merkel cell carcinoma: pathologic findings and prognostic factors. Curr Probl Cancer 2010 0.83
109 A brief history of melanoma: from mummies to mutations. Melanoma Res 2012 0.83
110 Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiol Biomarkers Prev 2013 0.82
111 Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther 2006 0.82
112 Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. Bioconjug Chem 2012 0.82
113 Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer 2015 0.82
114 In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm 2013 0.81
115 Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw 2013 0.81
116 Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004 0.81
117 Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010 0.81
118 Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther 2005 0.81
119 Extending the reach of BRAF-targeted cancer therapy. Lancet 2012 0.80
120 State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer 2008 0.80
121 Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg 2013 0.80
122 Management of familial melanoma and nonmelanoma skin cancer syndromes. Surg Oncol Clin N Am 2009 0.79
123 Targeted therapy for melanoma: is double hitting a home run? Nat Rev Clin Oncol 2012 0.79
124 Full-thickness grafts procured from skin overlying the sentinel lymph node basin; reconstruction of primary cutaneous malignancy excision defects. Ann Surg Oncol 2008 0.79
125 Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Canc Netw 2012 0.79
126 The contoured staged marginal and central surgical excision technique with en face histopathological analysis: useful additions in the armamentarium for treating and diagnosing melanoma in situ. Ann Surg Oncol 2009 0.79
127 A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 2004 0.79
128 Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer 2007 0.79
129 Surgical therapy of cutaneous melanoma. Semin Oncol 2007 0.78
130 The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol 2012 0.78
131 When will melanoma vaccines be proven effective? J Clin Oncol 2003 0.78
132 Completely regressed cutaneous melanocytic lesion revisited. Semin Oncol 2009 0.78
133 Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw 2005 0.78
134 Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol 2012 0.78
135 Individualizing follow-up for patients with early-stage melanoma. J Clin Oncol 2011 0.77
136 Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit Rev Oncol Hematol 2005 0.77
137 Nonsentinel node metastases in melanoma: do they reflect the biology of the tumor, the lymph node or the surgeon? : Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1. Ann Surg Oncol 2009 0.77
138 Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol 2012 0.77
139 The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am 2011 0.77
140 Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2003 0.77
141 How does interferon work? Does it even matter? Cancer 2002 0.76
142 A collision of diseases: chronic lymphocytic leukemia discovered during lymph node biopsy for melanoma. Ann Surg Oncol 2012 0.76
143 Chemoprevention of melanoma: theoretical and practical considerations. Cancer Control 2005 0.76
144 Primary tumor thickness as a prognostic factor in Merkel cell carcinoma: the next big thing? Ann Surg Oncol 2012 0.76
145 Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Ann Surg Oncol 2011 0.76
146 Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control 2013 0.76
147 Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res 2009 0.76
148 Unanswered questions in the management of stage I-III Merkel cell carcinoma. J Natl Compr Canc Netw 2014 0.76
149 How well are we taking care of melanoma patients in the USA? Ann Surg Oncol 2008 0.75
150 Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med 2011 0.75
151 The sentinel lymph node: more than just another blue lymph node. Cancer 2003 0.75
152 RE: A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest 2004 0.75
153 Feasibility of serial biopsies of large dysplastic nevi as a melanoma chemoprevention model. J Am Acad Dermatol 2011 0.75
154 What is the significance of the in transit or interval sentinel node in melanoma? Ann Surg Oncol 2011 0.75
155 Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. Ann Plast Surg 2016 0.75
156 Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J 2010 0.75
157 Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma? Drugs 2003 0.75
158 Melanoma vaccines: breakthrough or bust? Cancer Invest 2002 0.75
159 Melanoma and human leukocyte antigen status: the missing link? Ann Surg Oncol 2002 0.75
160 Has targeted therapy for melanoma made chemotherapy obsolete? Lancet Oncol 2013 0.75
161 How do we know when a lymph node dissection is adequate? Ann Surg Oncol 2011 0.75
162 Use and abuse of statistics in evidence-based medicine. J Clin Oncol 2002 0.75
163 Integrating molecular biomarkers into current clinical management in melanoma. Methods Mol Biol 2014 0.75
164 Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma: a roadmap for the future. Cancer 2010 0.75
165 Minimizing morbidity while preserving outcome after inguinal lymphadenectomy: navigating between scylla and charybdis. Ann Surg Oncol 2011 0.75
166 Identifying risk factors using a skin cancer screening program. Cancer Control 2013 0.75
167 Metastatic nevoid melanoma in a 4 1/2-year-old child. J Cutan Pathol 2003 0.75
168 Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg 2016 0.75
169 Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006 0.75
170 Introduction: Advanced cutaneous malignancies. Semin Oncol 2012 0.75
171 A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study. Invest New Drugs 2002 0.75
172 Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg 2016 0.75
173 POINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma. Oncology (Williston Park) 2016 0.75
174 Cytoreductive surgery for melanoma. Surg Oncol Clin N Am 2007 0.75
175 BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res 2016 0.75
176 Tumor vaccines: a role in preventing recurrence in melanoma? Am J Clin Dermatol 2002 0.75
177 Routine biopsy of Cloquet's node is of limited value in sentinel node positive melanoma patients. J Surg Oncol 2010 0.75
178 Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments? Semin Oncol 2010 0.75
179 The future of targeted therapy approaches in melanoma. Expert Opin Drug Discov 2009 0.75
180 Melanoma margins: the importance and need for more evidence-based trials. Arch Dermatol 2004 0.75